menu search

Gri bio announces partnership with the respiratory translational research collaboration to advance leading nkt regulation technology targeting earlier in the inflammatory cascade to modulate disease p

UK consortia brings together internationally recognized investigators in the UK’s leading centers of excellence to carry out experimental and early ...

October 17, 2023, 12:35 pm

Harmony stock tanks on study miss for narcolepsy drug: problems may be escalating

Harmony Biosciences' only product, WAKIX - pitolisant - has generated over $1 billion in net revenue since its launch. The company's Q2 2023 earnings ...

October 13, 2023, 4:01 pm

Aldeyra:upcoming pdufa, strong nda, long pipeline, decent cash

Aldeyra is a late-stage company developing therapies for immune-mediated diseases, with a focus on dry eye disease and allergic conjunctivitis. Their ...

September 22, 2023, 7:44 pm

Galecto (glto) down 71% as lung disease candidate fails

Galecto's (GLTO) shares fall as the mid-stage study of GB0139 to treat idiopathic pulmonary fibrosis fa...

August 16, 2023, 9:28 am

Galecto announces topline results from phase 2b galactic-1 trial of gb0139 for the treatment of idiopathic pulmonary fibrosis

Announces next steps for clinical development plan in severe liver diseases BOSTON, Aug. 15, 2023 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a...

August 15, 2023, 11:30 am

Galecto shares drop 65% as biotech halts development of lung-disease treatment

Shares of Galecto Inc. GLTO dropped 65% in premarket trading Tuesday after the biotech company said it would drop an investigational treatment for ...

August 15, 2023, 8:39 am

Fibrogen (fgen) plunges on failure of late-stage ipf study

FibroGen (FGEN) plummets on yet another pipeline setback. The phase III study, ZEPHYRUS-1, evaluating the safety and efficacy of pamrevlumab in patien...

June 27, 2023, 2:18 pm

Zevra therapeutics presents design of phase 2 clinical trial investigating kp1077 for the treatment of idiopathic hypersomnia (ih) at beyond sleepy 2023

Zevra is a corporate sponsor of the Hypersomnia Foundation and Beyond Sleepy Conference CELEBRATION, Fla., June 03, 2023 (GLOBE NEWSWIRE) — Zevra Th...

June 3, 2023, 11:30 am

Bristol myers (bmy) reports pulmonary fibrosis study results

Bristol Myers' (BMY) idiopathic pulmonary fibrosis drug reduces the rate of lung function decline in a ...

May 23, 2023, 1:39 pm

Immupharma shares jump 6.5% after fda update

ImmuPharma PLC (AIM:IMM, OTC:IMMPF) shares leapt 6.5% in late morning trading following encouraging news on its experimental drug P140. The US Food a...

May 18, 2023, 6:24 am

Immupharma says cidp trial will begin in the second half after meeting with us regulator

ImmuPharma PLC (AIM:IMM, OTC:IMMPF), a specialist drug discovery and development firm, has announced significant progress with its late-stage clinical...

May 18, 2023, 3:05 am

Immupharama eyes clinical trial progress

ImmuPharama PLC's focus for the current year will be on moving Lupuzor, its treatment for the autoimmune disease lupus, into a phase II/III clinical t...

May 11, 2023, 3:06 am

Vyne gains on preclinical data for ipf candidate

VYNE gains on positive preclinical data evaluating VYN201 for treating idiopathic pulmonary fibrosis....

April 20, 2023, 12:57 pm

Jazz pharmaceuticals to present advancements in neuroscience at american academy of neurology annual meeting

Eleven abstracts emphasize Jazz's leadership in neuroscience and commitment to advance understanding of sleep disorders, epilepsy and movement disorde...

April 19, 2023, 7:45 am

Immupharma rises 4% after it reveals headway with lead asset

Shares of ImmuPharma PLC (AIM:IMM, OTC:IMMPF) rose 4% to 2.33p following news of progress in the development of a second indication for its lead asset...

April 12, 2023, 8:42 am

Immupharma makes progress developing second indication for lead asset

ImmuPharma PLC (AIM:IMM, OTC:IMMPF) said the US Food & Drug Administration (FDA) has called a pre-investigational new drug (IND) meeting for May 16,�...

April 12, 2023, 2:40 am

Pliant therapeutics' bexotegrast shows promise for idiopathic pulmonary fibrosis

Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for fibrosis, inflammation, and related d...

March 3, 2023, 10:48 am

Valeo pharma obtains public reimbursement for onstryv in quebec expanding access to the drug for parkinson's patients

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) said Onstryv (safinamide) for the treatment of patients with Parkinson's disease is now listed for reimbursem...

February 7, 2023, 9:01 am

Fsd pharma says recruiting underway in phase 2 trial of fsd201 for treating chronic pain associated with idiopathic mcas

FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) said recruiting is underway for the Phase 2 clinical trial of FSD-PEA (FSD201) for the treatment of chronic p...

January 30, 2023, 9:09 am

Why pliant therapeutics stock is skyrocketing this week

The company's experimental idiopathic pulmonary fibrosis drug is showing a lot of promise....

January 26, 2023, 4:16 pm


Search within

Pages Search Results: